With the outbreak of the COVID-19 pandemic, policymakers have become increasingly concerned about the pharmaceutical supply chain—and ensuring the American public can access vital products. Yet even under the tremendous pressure of the pandemic, the supply chain proved itself to be remarkably resilient. That said, there are ways to enhance that resiliency —without resorting to rank protectionism—in the face of legitimate concerns about certain foreign trade practices, including China’s. Earlier this summer, R Street released a new white paper  which does exactly this: surveys the performance of supply chains in recent years and offers concrete policy recommendations.
We invite you to an online discussion about the future of pharmaceutical trade and ways that policymakers can strengthen the supply chain without reshoring all production back to the United States.
- [Moderator] Halie Craig, Associate Fellow, R Street Institute
- Clark Packard, Trade Policy Counsel and Resident Fellow, R Street Institute
- Bryan Riley, Director of the Free Trade Initiative, National Taxpayers Union
- Tiffany L. Smith, Senior Policy Adviser, Mayer Brown
- “white paper”: https://www.rstreet.org/wp-content/uploads/2021/07/Final-No.-236-1.pdf